NCT05234021View on ClinicalTrials.gov

HER2-directed Biosimilar in Breast Cancer: Real World ePRO

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
HER2-positive Breast CancerBiosimilarPatient Reported Outcome
Trial Locations (3)

8001

Onkologiepraxis Bellvue, Zurich

8010

Andreas Trojan, Horgen

8640

ZeTup, Rapperswil-Jona

Sponsors

Collaborators (1)

Palleos Healthcare GmbH
All Listed Sponsors
collaborator

University of Zurich

OTHER

collaborator

Palleos Healthcare GmbH

INDUSTRY

lead

OnkoZentrum Zürich AG

OTHER

NCT05234021 - HER2-directed Biosimilar in Breast Cancer: Real World ePRO | Biotech Hunter | Biotech Hunter